Yseop launches Yseop Copilot, a generative AI assistant for science writers

Yseop launches Yseop Copilot, a generative AI assistant for science writers

Join top executives in San Francisco July 11-12 to hear how leaders are integrating and optimizing AI investments for success. Learn more

Generative AI software company Siop today announced the launch of Yseop Copilot, a content automation tool tailored for regulated industries. According to the company, this next-generation offering aims to help life sciences companies streamline their automation requirements. The multimodal platform uses pre-trained large language models (LLMs) to empower science writers and improve their strategy skills and productivity within a secure, enclosed environment.

Yseop said Copilot allows science writers to control quality and maximize productivity. The company says that using this innovative solution, writers involved in hundreds of clinical studies have significantly reduced their writing time, resulting in greater consistency and reliability in their reports.

“Our new platform offers a range of applications that use specially trained LLMs to create a variety of documents for non-clinical, clinical, chemistry, manufacturing and control workflows. These documents are critical for compliance with regulatory requirements when submitting a drug for market approval,” Timothy Martin, Yseop EVP of Product, told VentureBeat. “We chose the name “Yseop Copilot” for our product because it represents Our Human-Centered Approach Our artificial intelligence serves as a tool to upskill medical and science writers, assisting them throughout the content generation process.

Comprehensive and intelligent process

The company emphasized its dedicated focus on regulated industries, such as BioPharma, when developing the digital assistant. Ensures accuracy of writing using proprietary prompts and validation methods while preserving traceability through citations.


Transform 2023

Join us in San Francisco July 11-12, where top executives will share how they integrated and optimized AI investments for success and avoided common pitfalls.

subscribe now

Additionally, Yseop said Copilot guarantees to host each customer’s data in a completely secure and private environment. This platform incorporates data-to-text (symbolic AI) and text-to-text (pre-trained open source LLM) techniques to provide regulated industries with a comprehensive and intelligent content automation process.

Compliant with GxP regulations and offering full auditability, the tool grants users instant access to pre-configured settings and complete control over automated content generation. By addressing critical data security concerns, it enables high-fidelity automation for both non-clinical and clinical documents.

Leverage Generative AI to streamline scientific documentation

Yseop says the current process of developing and delivering drugs to market often involves outsourcing to take advantage of cheap labor in different locations. However, this outsourcing approach often leads to various inefficiencies, including document management difficulties, accuracy, and consistency.

“By automating data processing and generating initial drafts of documents, Copilot enables medical and scientific authors to spend more time and attention providing critical insights into the drug development process,” said Martin. “We use a software platform, together with the LLM, that has been extensively trained on highly specific data to produce high-quality content for new medicines in development.”

Martin further explained that LLMs learn from training documents and serve as the central technology for generating narratives.

“The software provides control over the output of narratives and offers an audit trail, allowing medical writers to quickly validate narratives using evidence,” he said.

Help save and improve lives

These features help maintain model accuracy, ensure narrative consistency, and provide data transparency. Yseop Copilot can deliver transformative ROI by automating content generation and accelerating drug delivery to market, Martin said.

“This, in turn, translates into a significant impact on saving or improving more lives through the timely availability of new drug treatments,” he said.

The software platform integrates into customers’ workflows, providing the transparency and explainability needed to comply with GxP standards and industry requirements for drug delivery.

The technology can be extended to popular writing tools like Microsoft Word and business intelligence (BI) tools like PowerBI and Tableau.

“This ensures that our high-quality narratives are delivered directly within the environments where medical and science writers work, promoting narrative consistency across the company,” said Martin. “Managing routine tasks allows highly skilled medical and scientific writers to focus on their core strengths, which involve discovering new insights and contributing their expertise to more important problems.”

What is the future of Yseop?

Martin said Yseop seeks to lead a revolution in content automation by leveraging generative AI. Additionally, the company aims to improve the drug lifecycle by automating more drug delivery workflows and is also making substantial R&D investments to advance the capabilities of generative AI technology.

Yseop actively works with key pharmaceutical customers to understand their specific needs and challenges, said Martin. Additionally, the company engages with industry leaders and regulatory bodies to drive digital innovation in the field.

“Through these partnerships and collaborations, Yseop seeks to have a significant impact on improving the quality of human life,” said Martin.

VentureBeat’s mission it is to be a digital city square for technical decision makers to gain insights into transformative business technology and transactions. Discover our Briefings.